CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 504 resultados LastUpdate Última actualización 26/03/2023 [12:02:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days



Página1 de 21 nextPage   por página


COMPOSITIONS THAT BLOCK ACTIVATION OF THE SARS-COV-2 REPLICATION AND TRANSCRIPTION COMPLEX (RTC) AND METHODS OF USE THEREOF

NºPublicación: WO2023041985A2 23/03/2023

Solicitante:

NEW YORK UNIV IN ABU DHABICORPORATION [AE]
PERCIPALLE PIERGIORGIO [AE]
ESPOSITO GENNARO [AE]
ISAR BIOSCIENCE GMBH [DE]

Resumen de: WO2023041985A2

The invention provides nanobodies that bind with high affinity to SARS-CoV- 2 non-structural protein (Nsp), as well and compositions comprising the identified nanobodies and methods of use thereof to block activation of SARS-CoV-2 viral replication, and for the treatment or prevention of COVID-19.

traducir

RAPID DETECTION TEST FOR SARS-COV-2

NºPublicación: US2023090502A1 23/03/2023

Solicitante:

NLC PHARMA LTD [IL]

KR_20220151168_PA

Resumen de: US2023090502A1

The present invention is directed towards methods, compositions and kits for testing SARS-CO-V2 virus in a sample. The methods determine the presence of a viral 3CL protease by contacting the sample with a peptide compound capable of being cleaved by the protease to form peptide compound fragments. Detection of a peptide compound fragment confirms the presence of the virus.

traducir

SYNTHETIC HUMANIZED LLAMA NANOBODY LIBRARY AND USE THEREOF TO IDENTIFY SARS-COV-2 NEUTRALIZING ANTIBODIES

NºPublicación: WO2023044272A1 23/03/2023

Solicitante:

THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES [US]

Resumen de: WO2023044272A1

Methods for producing synthetic single-domain monoclonal antibody libraries using humanized llama nanobody framework sequences, libraries obtainable by the method, as well as antibodies selected from the libraries are described. In particular, synthetic single-domain monoclonal antibodies that specifically bind to the spike protein of SARS-CoV-2 and neutralize SARS-CoV-2 infection are described. Use of the disclosed antibodies for the detection, prophylaxis and treatment of SARS-CoV-2 infection is described.

traducir

COMPOSITION AND METHOD FOR DETECTING SARS-COV-2

NºPublicación: WO2023041564A1 23/03/2023

Solicitante:

PRIMER DESIGN LTD [GB]

Resumen de: WO2023041564A1

The invention relates to novel primers, probes, kits and methods for determining the presence or absence of SARS-CoV-2.

traducir

DETECTION OF SARS-COV-2

NºPublicación: WO2023041808A1 23/03/2023

Solicitante:

MIP DISCOVERY LTD [GB]

Resumen de: WO2023041808A1

A molecularly imprinted polymer comprises at least one recognition site that is complementary to a template molecule consisting of an amino acid sequence corresponding to a subsequence of the receptor binding domain of SARS-CoV-2 spike protein, wherein the amino acid sequence is no more than 50 amino acids in length and comprises a sequence selected from (i) NSNNLDSKVGG, (ii) NYNYLYRLFRKS, (iii) YRLFRKSNLKPF, (iv) STEIYQAGSTPC, (v) CNGVEGFNCYF,(vi) GSTPCNGVEGF, (vii) CYFPLQSYGFQP, (viii) GFQPTNGVGYQ and (ix) LQSYGFQPTNG. A method of preparing the molecularly imprinted polymer is also provided. Conjugates comprising the molecularly imprinted polymer and a fluorophore are also provided as are compositions containing the molecularly imprinted polymer and conjugates of the invention. The molecularly imprinted polymer, conjugate and compositions can be used in the detection of SARS-CoV-2.

traducir

PIV5-BASED CORONAVIRUS VACCINES AND METHODS OF USE THEREOF

NºPublicación: WO2023044505A2 23/03/2023

Solicitante:

CYANVAC LLC [US]

Resumen de: WO2023044505A2

The present invention provides constructs of the parainfluenza virus type-5 (PIV5) virus expressing the SARS-CoV-2 envelope spike (S) and nucleocapsid (N) proteins of SARS-CoV-2 variants for use as safe, stable, efficacious, and cost-effective vaccines against COVID-19.

traducir

ORAL VACCINE VIA DENTAL BACTERIA AND EMITTED PEPTIDES TO PREVENT COVID-19 INFECTION

NºPublicación: WO2023044494A2 23/03/2023

Solicitante:

KOTLYAR DAVID [US]

Resumen de: WO2023044494A2

Disclosed is a pharmaceutical composition to prevent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pharmaceutical composition comprising: genetically modified bacteria; sequences of small peptides; and pharmaceutical excipients, wherein the genetically modified oral bacteria are modified to translate, produce, and emit the sequences of small peptides which neutralize SARS-CoV-2 against COVID-19, wherein transgenic technology is used to modify the genetically modified oral bacteria to add genes in genetically modified oral bacteria that are transcribed to produce small peptides from the sequences of small peptides so added, wherein the sequences of small peptides show extreme binding and neutralization to SARS-CoV-2 but not to host proteins or processes, and wherein the pharmaceutical excipients aid the oral and/or nasal administration of the pharmaceutical composition.

traducir

ENGINEERED RECEPTORS AND MONOCLONAL ANTIBODIES FOR CORONAVIRUSES AND USES THEREOF

NºPublicación: WO2023044397A1 23/03/2023

Solicitante:

THE BOARD OF THE TRUSTEES OF THE UNIV OF ILLINOIS [US]
CYRUS BIOTECHNOLOGY INC [US]

Resumen de: WO2023044397A1

This disclosure relates generally to human ACE2 polypeptides that exhibit enhanced binding to the S protein of SARS-CoV-2, or increased affinity, that can be used as therapeutic agents in combination with monoclonal antibodies for the prophylaxis (pre- or post-exposure prophylaxis), or treatment of COVID-19, or disease caused by any coronavirus that utilizes ACE2 as a cellular receptor.

traducir

VIRUS-LIKE PARTICLE STABLY EXPRESSED BY ANIMAL CELLS AS VACCINE ANTIGEN AGAINST COVID-19 AND INFLUENZA VIRUS

NºPublicación: WO2023044344A1 23/03/2023

Solicitante:

ACAD SINICA
LIU FU TONG [US]

Resumen de: WO2023044344A1

The disclosure provides an animal cell stably expressing a virus-like particle (VLP). The disclosure also provides a method for manufacturing a virus-like particle, a virus-like particle, a vaccine composition, a method for preventing viral infection, and a method for producing antibodies.

traducir

APTAMER-BASED ELECTROCHEMICAL VIRUS DETECTOR AND METHODS THEREOF

NºPublicación: WO2023043540A1 23/03/2023

Solicitante:

THE JOHNS HOPKINS UNIV [US]

Resumen de: WO2023043540A1

A method for virus detection is disclosed, including introducing a biological media to an aptamer functionalized electrochemical sensor, generating an electrochemical signal from a. reaction between a virus and an aptamer, analyzing the electrochemical signal to determine presence of the virus, analyzing the electrochemical signal to determine a. quantity of the virus, and transmitting a presence of the virus and a quantity of the virus. A device for virus detection and method for fabricating a device for virus detection is also disclosed. The device for virus detection also includes an electrode, a functionalized aptamer anchored to the electrode, where an aptamer is functionalized such that it is specific to a virus, such as SARS-CoV-2 or an alternate virus or interest. The device for virus detection may be wearable.

traducir

ANGIOTENSIN CONVERTING ENZYME 2 RECEPTOR AND USE THEREOF

NºPublicación: WO2023043213A2 23/03/2023

Solicitante:

HAN JANG HYUN [US]
SEO MI YOUNG [KR]

Resumen de: WO2023043213A2

The present invention relates to an ACE2 ectodomain-redesigned ACE2 variant comprising: i) an ACE variant, lacking the enzymatic activity of ACE2, for capturing virions of Sars CoV-2 or variants thereof and ii) an ACE2 receptor, having the enzymatic activity of ACE2, for detecting virions of Sars CoV-2 or variants thereof, and a method for detecting virions of Sars CoV-2 or its variants by using same. Compared to conventional antigen and antibody diagnostic kits that detect past viral infections by using non-structural proteins of viruses and cannot distinguish past inactive viral infections from currently active viral infections, the present invention excludes causative substances that may come from past infection and inactive infection history in light of the feature wherein it detects virions of Sars CoV-2 or its variants that are currently active. In addition, in the present invention, the ACE2 variants were polymerized to increase the affinity for the virions by up to thousands of times, compared to the conventional ACE2, and the number of ACE2 molecules bound per virion was significantly increased to amplify the diagnostic signal.

traducir

PORTABLE STERILIZER

NºPublicación: WO2023043033A1 23/03/2023

Solicitante:

JANG PAL SOO [KR]

KR_102381489_B1

Resumen de: WO2023043033A1

A portable sterilizer is disclosed. A portable sterilizer, according to the present invention, comprises: a housing which has a water tank formed therein, and has a nozzle capable of spraying sterilizing water in a mist state, the nozzle being formed on one side of the housing so as to be exposed to the outside; an ozone gas supply unit formed inside the housing and supplying ozone gas to the nozzle; a compressed air supply unit formed inside the housing and supplying compressed air to the nozzle; and a water supply unit formed inside the housing and supplying water in the water tank to the nozzle, wherein the ozone gas and the compressed air are supplied in the form of a mixed gas to the nozzle, water is directly supplied to the nozzle, and the mixed gas and water are finally mixed inside the nozzle and then sprayed as sterilizing water in a mist state. According to the present invention, by spraying sterilizing water containing ozone in a mist state, it is possible to quickly sterilize and disinfect surfaces, indoor objects, and large areas exposed to coronavirus (SARS-CoV-2).

traducir

INHALABLE PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19)

NºPublicación: WO2023042928A1 23/03/2023

Solicitante:

KOREA UNITED PHARM INC [KR]

Resumen de: WO2023042928A1

The present invention relates to an inhalable pharmaceutical composition comprising budesonide or formoterol for preventing or treating COVID-19, and the composition exhibits more superb inhibitory effects on the virus than remdesivir injections and ciclesonide inhalations, which are known as therapeutic agents for COVID-19.

traducir

RECOMBINANT VACCINE AGAINST COVID-19 TO PRODUCE CELLULAR RESPONSE IN INDIVIDUALS WITH PRE-EXISTING IMMUNITY

NºPublicación: WO2023042181A1 23/03/2023

Solicitante:

LABORATORIO AVI MEX S A DE C V [MX]
CONSEJO NAC DE CIENCIA Y TECNOLOGIA [MX]
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI [US]

Resumen de: WO2023042181A1

A recombinant vaccine is described, which comprises an active Newcastle disease viral vector (NDV) having inserted an exogenous nucleotide sequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), without adjuvant, capable of generating a significant cellular response in T cells (CD4+ or CD8+) when stimulated with the S protein of the SARS-CoV-2 virus or proteins derived from it in individuals with previous immunity.

traducir

ALPACA-DERIVED NANOBODY AND USE THEREOF

NºPublicación: WO2023040834A1 23/03/2023

Solicitante:

INST OF MICROBIOLOGY CHINESE ACADEMY OF SCIENCES [CN]

CN_114891097_A

Resumen de: WO2023040834A1

Provided are an alpaca-derived nanobody that binds to SARS-CoV-2 RBD and the use thereof. The nanobody can effectively inhibit infection with the SARS-CoV-2 pseudovirus, and can be used for preventing, treating and/or detecting SARS-CoV-2 infections.

traducir

ALPACA-DERIVED NANOBODY AND APPLICATION THEREOF

NºPublicación: WO2023040835A1 23/03/2023

Solicitante:

INST OF MICROBIOLOGY CHINESE ACADEMY OF SCIENCES [CN]

CN_114933651_A

Resumen de: WO2023040835A1

Provided are an alpaca-derived nanobody combined with a SARS-CoV-2 RBD or an antigen-binding fragment thereof, and an application thereof. The nanobody may effectively inhibit SARS-CoV-2 pseudovirus infections, and may be used for the prevention, treatment and/or detection of SARS-CoV-2 infection.

traducir

FULLY HUMAN BROAD-SPECTRUM HIGH-NEUTRALIZING-ACTIVITY MONOCLONAL ANTIBODY AGAINST SARS-COV-2 AND USE THEREOF

NºPublicación: WO2023040627A1 23/03/2023

Solicitante:

ACAD OF MILITARY MEDICAL SCIENCE PLA [CN]

CN_113735969_A

Resumen de: WO2023040627A1

A fully human monoclonal antibody ZWD12 against SARS-CoV-2. The antibody is obtained by screening using a flow sorting-single cell PCR technology and has a unique CDR, and the antigen recognition epitope of the antibody is located in an RBD region of S1 protein. The EC50 of the antibody against the wild type of SARS-CoV-2 is 0.103 μg/mL, and the EC50 neutralizing the Beta strain is 0.069 μg/mL, and the EC50 neutralizing the Delta strain is 0.079 μg/mL, showing that ZWD12 has broad-spectrum neutralizing activity against the current major mutant strains.

traducir

MOUTH AND NOSE MASK HAVING VISUALLY TARGETED COLLECTION OF NOVEL CORONAVIRUS SAMPLE AND VISUAL WARNING

NºPublicación: WO2023040023A1 23/03/2023

Solicitante:

CENTRAL SOUTH UNIV [CN]

CN_113519939_A

Resumen de: WO2023040023A1

Disclosed is a mouth and nose mask having visually targeted collection of a novel coronavirus sample and a visual warning, belonging to the technical field of personal protection and pathogen sample collection. The mouth and nose mask comprises ear loops (3) as well as a mouth and nose mask body (1). An outermost layer of the mouth and nose mask (1) is an antifouling layer (7), an innermost layer is a skin-friendly layer (4), and a middle layer comprises a visible pathogen-targeted collection layer (5) or/and a filter layer (6). The visible pathogen-targeted collection layer (5) contains a color-changing material (8). The mouth and nose mask can visually target and collect saliva, droplet and aerosol-borne pathogens from suspected patients or patients with respiratory infectious diseases and also provides a warning function, thereby achieving the separation of the subject and the medical staff when collecting a novel coronavirus pathogen sample, reducing the risk of infection while increasing sample collection efficiency and reducing false negative rates.

traducir

IMMUNOCHROMATOGRAPHIC DETECTION REAGENT STRIP AND KIT COMPRISING SAME, AND APPLICATIONS OF BOTH

NºPublicación: WO2023040026A1 23/03/2023

Solicitante:

HANGZHOU BAOLIN BIOTECHNOLOGY CO LTD [CN]

CN_113777299_PA

Resumen de: WO2023040026A1

An immunochromatographic detection reagent strip and a kit comprising same, and applications of both, relating to the technical field of biological detection. According to the immunochromatographic detection reagent strip, fluorescent microspheres, latex, colloidal gold or colloidal carbon are coupled to a specific protein by using immunochromatography to obtain a specific protein complex. The specific protein comprises a novel coronavirus N protein first antibody, an influenza A virus NP protein first antibody and an influenza B virus NP protein first antibody, which are used to bind novel coronavirus N protein, influenza A virus NP protein and influenza B virus NP protein antigens. A nasopharyngeal swab, oropharyngeal swab, or saliva from a patient are then detected. The immunochromatographic detection reagent strip has the advantages of high sensitivity, high specificity and quantitative detection, and avoids weak positive sample missed detection and false positive sample false detection to the greatest extent.

traducir

NEW COMBINATION DRUG FOR TREATING CORONAVIRUS INFECTIONS, PHARMACEUTICAL COMPOSITION AND USE THEREOF

NºPublicación: WO2023040990A1 23/03/2023

Solicitante:

1GLOBE HEALTH INST NANJING [CN]

Resumen de: WO2023040990A1

A new combination drug or a new pharmaceutical composition containing nitazoxanide and used with atovaquone and/or ribavirin, and the use thereof in preventing or treating coronavirus infections, in particular the use in preventing or treating infections caused by SARS-CoV-2 and mutants thereof.

traducir

BAICALEIN DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF

NºPublicación: WO2023040733A1 23/03/2023

Solicitante:

SHANGHAI INST OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES [CN]
WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCIENCES [CN]

CN_115819391_PA

Resumen de: WO2023040733A1

Disclosed in the present invention are a class of baicalein derivatives, and a preparation method therefor and the uses thereof. The structure of the baicalein derivative of the present invention is as represented by the following general formula (I). According to pharmacological experiment verification, the baicalein derivative of the present invention exhibits an inhibitory activity against novel coronavirus, and can be used as an anti-novel coronavirus drug or a potential drug for treating related diseases caused by the novel coronavirus.

traducir

A novel medicament for immune modulation and treating chronic or hyper inflammation

NºPublicación: AU2021286756A1 23/03/2023

Solicitante:

ELKAZAZ MOHAMED FADLY

WO_2021249608_A2

Resumen de: AU2021286756A1

Present invention is a designation of a novel medicament for immune modulation and treating chronic or hyper inflammation. Its active ingredient is anabasine or its salt. It was designed for example to treat some of auto immune diseases permanently such as asthma and atopic dermatitis by one medication course, to stop the progression and development of diabetes type 2 in diabetics and restoring their blood sugar to normal with respect to administration in the disease early stages, to prevent the incidence and development of autoimmune Diabetes Type 1 resulted from T cell-mediated damage of pancreatic β-cells and loss of insulin production. Further, it plays a pivotal and protective role in treating hazardous infections caused by diverse pathogens to promote and accelerate recovery, including COVID -19 with its variants.

traducir

Chimeric conjugates for degradation of viral and host proteins and methods of use

NºPublicación: AU2021360898A1 23/03/2023

Solicitante:

DANA FARBER CANCER INSTITUTE INC

WO_2022081827_A1

Resumen de: AU2021360898A1

The present application describes chimeras which target and degrade essential viral proteins or host proteins involved in viral pathogenesis. In particular, the chimeras of this application combine a moiety that binds to a target protein (such as a coronaviral papain-like protease (PLpro), main protease (Mpro), or other non-structural proteins (e.g., NSP9 or NSP12); or a host protein, such as bromodomain 2, bromodomain 3, or bromodomain 4)), with a moiety that recruits a protein degrader, thereby degrading the target protein. In some instances, the chimera simultaneously induces p53, which itself has anti-viral activity, by engaging HDM2 as the protein degrader. The disclosure also relates to methods of using such chimeras in the prevention and treatment of viral infections, particularly viral infections (such as COVID-19) caused by coronaviruses (such as SARS-CoV-2).

traducir

Therapeutic and diagnostic VHH antibodies against SARS-CoV-2 and methods for their enhancement

NºPublicación: AU2021316668A1 23/03/2023

Solicitante:

MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WSS E V

WO_2022023484_A1

Resumen de: AU2021316668A1

The present invention pertains in the fields of antibody technology, protein engineering, medicine, pharmacology, infection biology, virology, and medical diagnostics. More specifically, the present disclosure provides VHH antibodies that prevent cell entry of and infection by SARS-CoV-2, a strategy for an enhanced block of the homotrimeric viral spike proteins by symmetry-matching VHH-fusions, implementations of this strategy, as well as VHH antibodies for sensitive detection of SARS-CoV2-infections.

traducir

Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections

Nº publicación: AU2021315818A1 23/03/2023

Solicitante:

PINETREE THERAPEUTICS INC

WO_2022026943_A2

Resumen de: AU2021315818A1

The present disclosure relates to fusion protein compositions and methods of reducing and treating viral infections. The fusion proteins include a polypeptide comprising a bl domain, or a derivative or fragment thereof, of a neuropilin; an ACE2 domain, or a derivative or a fragment thereof, of an angiotensin converting enzyme 2; and or an immunoglobulin domain. Both the bl and ACE2 domains are capable of binding to a coat protein of a virus selected from the group consisting of herpesviridae, papillomaviridae, coronaviridae, flaviviridae, togaviridae, bomaviridae, bunyaviridae, filoviridae, orthomyxoviridae, paramyxoviridae, pneumoviridae, and retro viridae. In some embodiments, the bl domain, or a derivative or fragment thereof, and/or the (ACE2) domain, can be used to specifically bind S proteins of COVID-19 particles.

traducir

Página1 de 21 nextPage por página

punteroimgVolver